201106-biogen-alzheimers-mn-11350_7340b8f11d4c4ae6f822bbec2f573972.jpg

  • November 6, 2020
  • 0
  • 2 Views

In this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer’s disease research in a laboratory at the drugmaker’s headquarters in Cambridge, Mass. On Friday, Nov. 6, 2020, a panel of outside experts will meet to advise the Food and Drug Administration on the drug, called aducanumab from Biogen Inc. and Japan’s Eisai Co. The drug does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. (David A. White/Biogen via AP)


Upstate News Headlines

PHP Code Snippets Powered By : XYZScripts.com